{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:04:36Z","timestamp":1773079476606,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1007\/s11910-003-0005-1","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T12:05:59Z","timestamp":1180699559000},"page":"289-295","source":"Crossref","is-referenced-by-count":11,"title":["Parkinson\u2019s disease: Is the initial treatment established?"],"prefix":"10.1007","volume":"3","author":[{"given":"J. Eric","family":"Ahlskog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5_CR1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448\u2013458.The risk of either dyskinesias or motor fluctuations is approximately 40% after 4 to 6 years of levodopa treatment. However, these are incidence figures and do not take into account that these motor complications may be trivial or abolished with levodopa dose adjustments.","journal-title":"Mov Disord"},{"key":"5_CR2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archneur.59.1.102","volume":"59","author":"H Apaydin","year":"2002","unstructured":"Apaydin H, Ahlskog JE, Parisi JE, et al.: Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002, 59:102\u2013112.","journal-title":"Arch Neurol"},{"key":"5_CR3","first-page":"32","volume":"40","author":"CW Olanow","year":"1990","unstructured":"Olanow CW: Oxidation reactions in Parkinson\u2019s disease. Neurology 1990, 40:32\u201337.","journal-title":"Neurology"},{"key":"5_CR4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ana.410320616","volume":"32","author":"S Fahn","year":"1992","unstructured":"Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson\u2019s disease: evidence supporting it [review]. Ann Neurol 1992, 32:804\u2013812.","journal-title":"Ann Neurol"},{"key":"5_CR5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0733-8619(05)70036-0","volume":"19","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE: Parkinson\u2019s disease: medical and surgical treatment. Neurol Clin 2001, 19:579\u2013605.","journal-title":"Neurol Clin"},{"key":"5_CR6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H","volume":"14","author":"Y Agid","year":"1999","unstructured":"Agid Y, Ahlskog E, Albanese A, et al.: Levodopa in the treatment of Parkinson\u2019s disease: a consensus meeting. Mov Disord 1999, 14:911\u2013913.","journal-title":"Mov Disord"},{"key":"5_CR7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.870130605","volume":"13","author":"A Schrag","year":"1998","unstructured":"Schrag A, Ben-Shlomo Y, Brown R, et al.: Young-onset Parkinson\u2019s disease revisited-clinical features, natural history, and mortality. Mov Disord 1998, 13:885\u2013894.","journal-title":"Mov Disord"},{"key":"5_CR8","first-page":"464","volume":"48","author":"MD Muenter","year":"2000","unstructured":"Muenter MD, Ahlskog JE: Dopa dyskinesias and fluctuations are not related to dopa treatment duration. Ann Neurol 2000, 48:464.","journal-title":"Ann Neurol"},{"key":"5_CR9","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.45.3_Suppl_3.S13","volume":"45","author":"Y Mizuno","year":"1995","unstructured":"Mizuno Y, Kondo T, Narabayashi H: Pergolide in the treatment of Parkinson\u2019s disease. Neurology 1995, 45:S13-S21.","journal-title":"Neurology"},{"key":"5_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","volume":"55","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Bracco F, Chouza C, et al.: Early treatment of Parkinson\u2019s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998, 55:23\u201330.","journal-title":"Drugs"},{"key":"5_CR11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks D, Korczyn AD, et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484\u20131491.Clinical trials comparing initial dopamine agonist with levodopa therapy consistently have reported a lower subsequent frequency of dyskinesias and motor fluctuations with agonist treatment. Levodopa, however, has consistently been significantly more efficacious.","journal-title":"N Engl J Med"},{"key":"5_CR12","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","volume":"284","author":"Parkinson Study Group","year":"2000","unstructured":"Parkinson Study Group: A randomized controlled trial comparing the agonist pramipexole with levodopa as initial dopaminergic treatment for Parkinson\u2019s disease. JAMA 2000, 284:1931\u20131938.Clinical trials comparing initial dopamine agonist with levodopa therapy consistently have reported a lower subsequent frequency of dyskinesias and motor fluctuations with agonist treatment. Levodopa, however, has consistently been significantly more efficacious.","journal-title":"JAMA"},{"key":"5_CR13","first-page":"A82","volume":"58","author":"AL Whone","year":"2002","unstructured":"Whone AL, Remy P, Davis MR, et al.: The REAL-PET study: slower progression in early Parkinson\u2019s disease treated with ropinirole compared with l-dopa. Neurology 2002, 58:A82-A83.Chronic ropinirole therapy resulted in a slower rate of decline of striatal 18F-dopamine compared with levodopa treatment.","journal-title":"Neurology"},{"key":"5_CR14","doi-asserted-by":"crossref","first-page":"A81","DOI":"10.1212\/WNL.58.5.679","volume":"58","author":"RG Holloway","year":"2002","unstructured":"Holloway RG, for the Parkinson Study Group: Pramipexole versus levodopa as initial treatment for Parkinson disease: a four-year randomized controlled trial. Neurology 2002, 58:A81-A82.Clinical trials comparing initial dopamine agonist with levodopa therapy consistently have reported a lower subsequent frequency of dyskinesias and motor fluctuations with agonist treatment. Levodopa, however, has consistently been significantly more efficacious.","journal-title":"Neurology"},{"key":"5_CR15","first-page":"369","volume":"5","author":"RY Uitti","year":"1996","unstructured":"Uitti RY, Ahlskog JE: Comparative review of dopamine receptor agonists in Parkinson\u2019s disease. Cent Nerv Syst Drugs 1996, 5:369\u2013388.","journal-title":"Cent Nerv Syst Drugs"},{"key":"5_CR16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653\u20131661. Chronic pramipexole therapy was associated with a significantly slower rate of decline of striatal 123I-\u00e0-CIT uptake, as assessed by single photon emission computed tomography. Those treated with pramipexole alone had results similar to those who supplemented their pramipexole treatment with levodopa. 123I-\u03b2-CIT binds to the dopamine transporter, a biomarker of dopaminergic neurons.","journal-title":"JAMA"},{"key":"5_CR17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3565(24)29360-5","volume":"298","author":"HL Kimmel","year":"2001","unstructured":"Kimmel HL, Joyce AR, Carroll FI, Kuhar MJ: Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 2001, 298:129\u2013140.Dopamine transporter is a highly regulated protein with turnover influenced by dopamine agonist and levodopa administration.","journal-title":"J Pharmacol Exp Ther"},{"key":"5_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4","volume":"47","author":"CS Lee","year":"2000","unstructured":"Lee CS, Samii A, Sossi V, et al.: In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson\u2019s disease. Ann Neurol 2000, 47:493\u2013503.","journal-title":"Ann Neurol"},{"key":"5_CR19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.410350421","volume":"35","author":"GR Uhl","year":"1994","unstructured":"Uhl GR, Walther D, Mash D, et al.: Dopamine transporter messenger RNA in Parkinson\u2019s disease and control substantia nigra neurons. Ann Neurol 1994, 35:494\u2013498.","journal-title":"Ann Neurol"},{"key":"5_CR20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0169-328X(95)00278-Z","volume":"36","author":"KA Harrington","year":"1996","unstructured":"Harrington KA, Augood SJ, Kingsbury AE, et al.: Dopamine transporter (DAT) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson\u2019s disease. Brain Research. Mol Brain Res 1996, 36:157\u2013162.","journal-title":"Mol Brain Res"},{"key":"5_CR21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.870120609","volume":"12","author":"JN Joyce","year":"1997","unstructured":"Joyce JN, Smutzer G, Whitty CJ, et al.: Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson\u2019s, Alzheimer\u2019s with parkinsonism, and Alzheimer\u2019s disease. Mov Disord 1997, 12:885\u2013897.","journal-title":"Mov Disord"},{"key":"5_CR22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0006-2952(96)00898-2","volume":"53","author":"L Zhang","year":"1997","unstructured":"Zhang L, Coffey LL, Reith ME: Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem Pharmacol 1997, 53:677\u2013688.","journal-title":"Biochem Pharmacol"},{"key":"5_CR23","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1074\/jbc.272.24.15541","volume":"272","author":"RA Vaughan","year":"1997","unstructured":"Vaughan RA, Huff RA, Uhl GR, Kuhar MJ: Protein kinase Cmediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 1997, 272:15541\u201315546.","journal-title":"J Biol Chem"},{"key":"5_CR24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.0.CO;2-K","volume":"30","author":"ZB Pristupa","year":"1998","unstructured":"Pristupa ZB, McConkey F, Liu F, et al.: Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 1998, 30:79\u201387.","journal-title":"Synapse"},{"key":"5_CR25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1471-4159.1993.tb02185.x","volume":"61","author":"SM Meiergerd","year":"1993","unstructured":"Meiergerd SM, Patterson TA, Schenk JO: D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 1993, 61:764\u2013767.","journal-title":"J Neurochem"},{"key":"5_CR26","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1523\/JNEUROSCI.18-24-10304.1998","volume":"18","author":"M Batchelor","year":"1998","unstructured":"Batchelor M, Schenk JO: Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine. J Neurosci 1998, 18:10304\u201310309.","journal-title":"J Neurosci"},{"key":"5_CR27","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1212\/WNL.56.11.1559","volume":"56","author":"M Guttman","year":"2001","unstructured":"Guttman M, Stewart D, Hussey D, et al.: Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001, 56:1559\u20131564.Levodopa and pramipexole differentially affected striatal 123I-\u00e0-CIT single photon emission computed tomography outcomes in a 6-week trial, suggesting a pharmacologic effect on dopamine transporter regulation.","journal-title":"Neurology"},{"key":"5_CR28","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y","volume":"14","author":"JE Ahlskog","year":"1999","unstructured":"Ahlskog JE, Uitti RJ, O\u2019Connor MK, et al.: The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson\u2019s disease. Mov Disord 1999, 14:940\u2013946.","journal-title":"Mov Disord"},{"key":"5_CR29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J","volume":"14","author":"RB Innis","year":"1999","unstructured":"Innis RB, Marek KL, Sheff K, et al.: Effect of treatment with Ldopa\/ carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999, 14:436\u2013442.","journal-title":"Mov Disord"},{"key":"5_CR30","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/00004647-200011000-00010","volume":"20","author":"E Nurmi","year":"2000","unstructured":"Nurmi E, Bergman J, Eskola O, et al.: Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 2000, 20:1604\u20131609.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5_CR31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","volume":"35","author":"PA Ballard","year":"1985","unstructured":"Ballard PA, Tetrud JW, Langston JW: Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985, 35:949\u2013956.","journal-title":"Neurology"},{"key":"5_CR32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0002-9149(00)01171-1","volume":"86","author":"WC Cromwell","year":"2000","unstructured":"Cromwell WC, Ziajka PE: Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. Am J Cardiol 2000, 86:1123\u20131127.","journal-title":"Am J Cardiol"},{"key":"5_CR33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archneur.59.2.213","volume":"59","author":"S Locatelli","year":"2002","unstructured":"Locatelli S, Lutjohann D, Schmidt HH, et al.: Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Evidence that simvastatin affects cholesterol metablism in the human brain. Arch Neurol 2002, 59:213\u2013216.","journal-title":"Arch Neurol"},{"key":"5_CR34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ana.410410308","volume":"41","author":"R Torstenson","year":"1997","unstructured":"Torstenson R, Hartvig P, Langstrom B, et al.: Differential effects of levodopa on dopaminergic function in early and advanced Parkinson\u2019s disease. Ann Neurol 1997, 41:334\u2013340.","journal-title":"Ann Neurol"},{"key":"5_CR35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1212\/WNL.52.1.120","volume":"52","author":"A Ekesbo","year":"1999","unstructured":"Ekesbo A, Rydin E, Torstenson R, et al.: Dopamine autoreceptor function is lost in advanced Parkinson\u2019s disease. Neurology 1999, 52:120\u2013125.","journal-title":"Neurology"},{"key":"5_CR36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/BF02436753","volume":"18","author":"GM Knudsen","year":"1995","unstructured":"Knudsen GM, Hasselbalch S, Toft PB, et al.: Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria. J Inherited Metab Dis 1995, 18:653\u2013664.","journal-title":"J Inherited Metab Dis"},{"key":"5_CR37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00314504","volume":"236","author":"F Boomsma","year":"1989","unstructured":"Boomsma F, Meerwaldt JD, Man in\u2019t Veld AJ, et al.: Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-Omethyl-dopa. J Neurol 1989, 236:223\u2013230.","journal-title":"J Neurol"},{"key":"5_CR38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1212\/WNL.34.2.198","volume":"34","author":"CD Ward","year":"1984","unstructured":"Ward CD, Trombley IK, Calne DB, Kopin IJ: L-dopa decarboxylation in chronically treated patients. Neurology 1984, 34:198\u2013201.","journal-title":"Neurology"},{"key":"5_CR39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/00912700022009585","volume":"40","author":"R Durso","year":"2000","unstructured":"Durso R, Evans JE, Josephs E, et al.: Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000, 40:854\u2013860.","journal-title":"J Clin Pharmacol"},{"key":"5_CR40","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","volume":"52","author":"S Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE, et al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908\u20131910.","journal-title":"Neurology"},{"key":"5_CR41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","volume":"58","author":"JM Miyasaki","year":"2002","unstructured":"Miyasaki JM, Martin W, Suchowersky O, et al.: Practice parameter: initiation of treatment for Parkinson\u2019s disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002, 58:11\u201317.","journal-title":"Neurology"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-003-0005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-003-0005-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-003-0005-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T21:17:23Z","timestamp":1737062243000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-003-0005-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["5"],"URL":"https:\/\/doi.org\/10.1007\/s11910-003-0005-1","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}